EDIT Nov 2024 10.000 call
| Previous close | 0.3200 |
| Open | 0.5000 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 10.00 |
| Expiry date | 2024-11-15 |
| Day's range | 0.3200 - 0.5500 |
| Contract range | N/A |
| Volume | |
| Open interest | 243 |
GuruFocus.comDirector Jessica Hopfield Acquires 45,000 Shares of Editas Medicine Inc (EDIT)
On May 13, 2024, Jessica Hopfield, Director at Editas Medicine Inc (NASDAQ:EDIT), purchased 45,000 shares of the company, as reported in the SEC Filing.
GlobeNewswireEditas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June
CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that two abstracts, including one oral presentation and one poster presentation, detailing clinical data from the RUBY and EdiTHAL trials of renizgamglogene autogedtemcel (reni-cel) have been accepted for presentation at the European Hematology Association (EHA) Hybrid Congress being held June 13-16, 2024, in Madrid, Spain, and via livestream. Clinical d
Simply Wall St.Editas Medicine, Inc. (NASDAQ:EDIT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Editas Medicine, Inc. ( NASDAQ:EDIT ) just released its latest quarterly report and things are not looking great...
